Flash Finance

Indoco Remedies LimitedINDOCOCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹245.65
MCap ₹2,264 Cr · P/E n/m
Indoco Remedies Limited — Stock analysis & AI research Indoco Remedies Limited — Seasonality — best & worst months Indoco Remedies Limited — Technical indicators & charts Indoco Remedies Limited — Technical setup — score, trend, support & resistance Indoco Remedies Limited — Live exchange announcements
📈 Bullish EMA Alignment📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹466 Cr
Sales · Jun 2026
+6.5% YoY
₹40 Cr
Operating Profit · Jun 2026
+126.7% YoY
8.5%
OPM % · Jun 2026
+112.5% YoY
₹65 Cr
Net Profit · Jun 2026
+280.0% YoY
₹7.09
EPS · Jun 2026
+279.9% YoY

📝 Indoco Remedies Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Indoco Remedies Limited reported revenue of ₹466 crore for the quarter ended June 2026 (Q1 FY27), up 6.5% from ₹438 crore in the same quarter last year, and down 2.1% sequentially over the March 2026 quarter.

The company swung to a net profit of ₹65 crore from a net loss of ₹36 crore a year earlier. Earnings per share (EPS) came in at ₹7.09.

Operating profit stood at ₹40 crore — an operating margin (OPM) of 8.5%, compared with 4.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Indoco Remedies Limited posted revenue of ₹1,844 crore, a growth of 10.7% over FY25, with a net loss of ₹99 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,872 crore with a net profit of ₹3 crore.

Valuation snapshot

At the current price of ₹245.65, INDOCO has a market capitalisation of ₹2,264 crore and a P/E that is not meaningful, because trailing profit is close to zero.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 20th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 58.86%, foreign institutional investors (FIIs) 0.94%, domestic institutional investors (DIIs) 18.15%, public shareholders 21.90% of Indoco Remedies Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹2,264 Cr
Current Price ?
₹245.7
P/E ?
n/m
Industry P/E ?
37.20
P/B ?
2.41
P/S ?
1.21
P/FCF ?
24.88
Enterprise Value ?
₹3,354 Cr
EV/EBITDA ?
20.35
PEG ?
N/A
Earnings Yield ?
1.0%
Dividend Yield ?
0.08%
Profitability & Returns
Sales (TTM) ?
₹1,872 Cr
OPM ?
8.8%
Profit after tax (TTM) ?
₹3 Cr
EPS (TTM) ?
₹0.35
ROCE ?
1.0%
ROE ?
0.3%
ROA ?
0.1%
Growth
Sales — latest qtr ?
₹466 Cr
PAT — latest qtr ?
₹65 Cr
YoY qtr sales growth ?
6.5%
YoY qtr profit growth ?
280.0%
Sales growth (3y) ?
3%
Sales growth (5y) ?
8%
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹1,090 Cr
Debt to Equity ?
1.16
Interest Coverage ?
0.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
58.86%
Change in promoter holding ?
-0.04%
Pledged percentage ?
N/A
Market
Return 3 months ?
-0.7%
Return 6 months ?
11.9%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 428426482459450431433411390438485445476466 +6.5% -2.1%
Operating Profit 6561716349484012-11843325040 +126.7% -20.5%
Other Income 00423121221-543 +112.3% -13.5%
Interest 9881012141816182625264628 +8.3% -38.5%
Depreciation 1820212426282929293032323235 +16.3% +7.9%
Profit Before Tax 39344623337-5-31-46-37-14-31-2578 +312.0% +410.9%
Net Profit 26243516222-10-28-41-36-9-29-2465 +280.0% +372.7%
EPS 2.802.623.821.692.390.20-1.09-3.08-4.48-3.94-1.00-3.23-2.347.09 +279.9% +403.0%
OPM % 15.1% 14.3% 14.8% 13.7% 10.9% 11.1% 9.3% 2.9% -0.2% 4.0% 8.9% 7.2% 10.5% 8.5% +112.5% -19.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,665 Cr ₹1,844 Cr ₹1,872 Cr +10.7%
Operating Profit ₹99 Cr ₹143 Cr ₹165 Cr +43.6%
OPM % 5.96% 7.73% 8.80% +29.7%
NPM % -4.68% -5.35% 0.17% -14.3%
Other Income ₹5 Cr ₹1 Cr ₹3 Cr -74.5%
Depreciation ₹114 Cr ₹126 Cr ₹131 Cr +10.6%
Interest ₹66 Cr ₹123 Cr ₹125 Cr +85.2%
EBIT ₹-15 Cr ₹17 Cr ₹34 Cr +214.1%
PBT ₹-74 Cr ₹-106 Cr ₹8 Cr -42.8%
Tax ₹4 Cr ₹-5 Cr ₹8 Cr -229.3%
Net Profit ₹-78 Cr ₹-99 Cr ₹3 Cr -26.5%
EPS ₹-8.45 ₹-10.51 ₹0.52 -24.4%
Material Cost ₹537 Cr ₹297 Cr ₹296 Cr -44.8%
Employee Cost ₹394 Cr ₹210 Cr ₹205 Cr -46.6%
Extraordinary Items ₹1 Cr ₹-1 Cr ₹97 Cr -153.5%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 18181818 +0.0%
Reserves 1,0101,0911,004921 -8.3%
Borrowings 3336729941,090 +9.7%
Other Liabilities 297363414564 +36.2%
Total Liabilities 1,6582,1452,4302,593 +6.7%
Fixed Assets 6789549971,255 +25.9%
CWIP 11412532128 -91.3%
Investments 2911 +0.0%
Other Assets 8641,0571,1111,309 +17.8%
Total Assets 1,6582,1452,4302,593 +6.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 17915595192 +102.1%
Cash from Investing Activity -208-432-339-102 +69.9%
Cash from Financing Activity 23280241-77 -132.0%
Net Cash Flow -74-314 +566.7%
Free Cash Flow -27-269-25791 +135.4%
CFO/OP 84%75%112%140% +25.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 77827797 +26.0%
Inventory Days 228230307273 -11.1%
Days Payable 86100152208 +36.8%
Cash Conversion Cycle 219212232162 -30.2%
Working Capital Days 82623921 -46.2%
ROCE % 17%10%-0%1% —

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 58.90%58.90%58.90%58.86% -0.1%
FIIs 1.22%1.25%1.10%0.94% -14.5%
DIIs 18.96%18.16%18.15%18.15% +0.0%
Public 20.82%21.60%21.76%21.90% +0.6%
Others 0.09%0.09%0.09%0.14% +55.6%
No. of Shareholders 33,12933,31932,65932,276 -1.2%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Indoco Remedies Limited's revenue in Q1 FY27?
Indoco Remedies Limited reported revenue of ₹466 crore for the quarter ended June 2026 (Q1 FY27), up 6.5% from ₹438 crore in the same quarter last year, and down 2.1% sequentially over the March 2026 quarter.
What was Indoco Remedies Limited's net profit in Q1 FY27?
The company swung to a net profit of ₹65 crore from a net loss of ₹36 crore a year earlier. Earnings per share (EPS) came in at ₹7.09.
What is INDOCO's market capitalisation and P/E ratio?
At the current price of ₹245.65, INDOCO has a market capitalisation of ₹2,264 crore and a P/E that is not meaningful, because trailing profit is close to zero.
Who owns Indoco Remedies Limited? (shareholding pattern)
As of Mar 2026, promoters held 58.86%, foreign institutional investors (FIIs) 0.94%, domestic institutional investors (DIIs) 18.15%, public shareholders 21.90% of Indoco Remedies Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI